Please login to the form below

Not currently logged in
Email:
Password:

Infinity Pharmaceuticals

This page shows the latest Infinity Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

BMS teams up with Infinity Pharmaceuticals for Opdivo study

BMS teams up with Infinity Pharmaceuticals for Opdivo study

Bristol-Myers Squibb and Infinity Pharmaceuticals have teamed up to study tumour resistance to checkpoint inhibitors in BMS' immuno-oncology drug Opdivo (nivolumab). ... Our agreement with Infinity builds on our continued focus to bring forward potential

Latest news

  • FDA sets standard review for Gilead's idelalisib in NHL FDA sets standard review for Gilead's idelalisib in NHL

    Its nearest competitor is Infinity Pharmaceuticals' IPI145 which is in phase II trials.

  • Gilead halts leukaemia study on positive results Gilead halts leukaemia study on positive results

    last month - although another candidate from Infinity Pharmaceuticals' called IPI145 has shown early promise in phase I dose-ranging studies and is now in phase II.

  • Getting the GIST

    One HSP90 inhibitor, retaspimycin (IPI-504, Infinity Pharmaceuticals), advanced into phase III clinical trials in GIST patients pre-treated with at least imatinib and sunitinib; however, this trial (RING trial) had ... Krystexxa (Savient Pharmaceuticals).

  • Biologics buoyant

    Licenser/Partner or Acquirer. Product/Technology. Development status. Headline ($m). Arena Pharmaceuticals/Eisai. ... 508. Intellikine/Infinity Pharmaceuticals. INK1197 and other PI3K inhibitors – inflammation/oncology. Preclinical .

  • Pharma news in brief

    Novartis and Infinity in cancer drug deal. US biotech firm, Infinity Pharmaceuticals, has signed a deal worth up to $400m with Novartis to develop cancer treatments. ... Total payments could reach $400m if Infinity meets certain milestones related to

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    Licensor Acquired/ Licensee Acquirer. Product/ Technology. Deal Type. Headline ($m). Selexys Pharmaceuticals/ Novartis. ... development and commercialisation. 45. Infinity Pharmaceuticals/ Verastem. Duvelisib, oral inhibitor of PI3K‐delta and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Gamida Cell strengthens leadership team Gamida Cell strengthens leadership team

    He has also served as vice president, business and corporate development at Infinity Pharmaceuticals, where he was responsible for the company’s in-licensing, out-licensing and alliance management activities.

  • Decibel Therapeutics expands leadership team Decibel Therapeutics expands leadership team

    Prior to this, Keilty served as vice president of information technology and informatics at Infinity Pharmaceuticals, and held a number of positions at Millennium Pharmaceuticals working with the company's core

  • Decibel Therapeutics appoints former Biogen exec as president and CEO Decibel Therapeutics appoints former Biogen exec as president and CEO

    Prior to Biogen, he founded Infinity Pharmaceuticals, and served as its chief executive officer and chairman of the board of directors. ... During his 30 years of biotech industry experience, Holtzman also served as the chief business officer at

  • Ardelyx appoints William Bertrand Jr to board of directors Ardelyx appoints William Bertrand Jr to board of directors

    Executive VP of Infinity Pharmaceuticals joins the team. Ardelyx has appointed William Bertrand Jr to its board of directors. ... Bertrand is currently executive VP of general counsel for Infinity Pharmaceuticals and prior to this he served as senior VP

  • Warp Drive Bio names Gregory Verdine as CEO Warp Drive Bio names Gregory Verdine as CEO

    Dr Nichols joins as chief operating officer from Resolvyx Pharmaceuticals, where he was president and chief operating officer. ... Dr Adams is president of R&D at Infinity Pharmaceuticals having served at Millennium Pharmaceuticals, where he had global

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics